KROS logo

KROS
Keros Therapeutics Inc

1,208
Mkt Cap
$222.66M
Volume
162,928.00
52W High
$22.55
52W Low
$9.79
PE Ratio
-3.74
KROS Fundamentals
Price
$11.25
Prev Close
$11.39
Open
$11.51
50D MA
$11.38
Beta
0.93
Avg. Volume
334,025.01
EPS (Annual)
$2.30
P/B
0.78
Rev/Employee
$3.13M
$500.28
Loading...
Loading...
News
all
press releases
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.
Zacks
News Placeholder
More News
News Placeholder
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced against uncertain milestone-driven revenue.
Zacks
News Placeholder
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans, orphan status and early clinical signals.
Zacks
News Placeholder
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
KROS posts a wider Q1 loss as revenues fall due to the absence of license revenues. The company advances rinvatercept and elritercept studies.
Zacks
News Placeholder
Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates
Keros Therapeutics (KROS) delivered earnings and revenue surprises of -31.52% and -93.01%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates
Aytu BioPharma, Inc. (AYTU) delivered earnings and revenue surprises of -70.97% and +3.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of +2.17% and -2.26%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts
Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have earned a consensus rating of "Hold" from the nine analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and four ha...
MarketBeat
News Placeholder
Keros Therapeutics (KROS) to Release Quarterly Earnings on Tuesday
Keros Therapeutics (NASDAQ:KROS) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...
MarketBeat
News Placeholder
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
Keros heads into 2026 with three key catalysts, including DMD study start, ALS regulatory talks, and Takeda progress, that could reshape investor sentiment.
Zacks
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available